Skip to main content

Table 1 Demographics and characteristics of CSF biomarkers and PET quantification measures, overall and by cohort. All the characteristics shown in this table were statistically different (p < 0.001) between cohorts

From: Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

  ALL (n = 516) ALFA+ (n = 205) ADNI (n = 311)
Age, mean (SD) [range] 69.13 (9.10) [50–92] 61.01 (4.85) [50–74] 74.48 (7.07) [56–92]
Women, n (%) 286 (55.4) 134 (65.4) 152 (48.9)
Education, years mean (SD) 14.98 (3.37) 13.49 (3.58) 15.96 (2.82)
APOE-ε4 carriers, n (%) 260 (50.4) 81 (39.5) 179 (57.6)
Positive Aβ42, n (%) 273 (52.9) 60 (29.3) 213 (68.5)
Positive pTau, n (%) 323 (62.6) 56 (27.3) 267 (85.9)
Positive tTau, n (%) 294 (57.0) 50 (24.4) 244 (78.5)
Positive pTau/Aβ42, n (%) 258 (50.0) 24 (11.7) 234 (75.2)
Positive tTau/Aβ42, n (%) 246 (47.7) 21 (10.2) 225 (72.3)
Diagnostic, n (%) CN/MCI/AD 256 / 237 / 23 (49.6)/(45.9)/(4.5) 205 / 0 / 0 (100)/(0)/(0) 36 / 237 / 23 (11.6)/(76.2)/(7.4)
Time difference CSF-PET, days mean (SD) [range] 45.2 (60.3) [0–343] 97.1 (65.1) [14–343] 11.0 (17.2) [0–126]
  1. Aβ β-amyloid, AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE Apoliprotein E, CN cognitively normal, MCI mild cognitive impaired participants, pTau phosphorylated tau, SD standard deviation, tTau total tau